ICCVAM report available
This article was originally published in The Rose Sheet
National Toxicology Program's Interagency Center for the Evaluation of Alternative Toxicological Methods (NICEATM) announces availability of "Biennial Progress Report: Interagency Coordinating Committee on the Validation of Alternative Methods: 2006-2007" in Oct. 23 Federal Register notice. Report describes ICCVAM activities, test method recommendations, and other progress made during 2006-2007 period. Notice highlights ICCVAM's recommendation of first non-animal ocular safety methods and two cell-based assays for acute poisoning, as well as its evaluation of five tests for pyrogenicity. Biennial Report can be accessed at ICCVAM Web site
You may also be interested in...
Formycon’s CEO has offered the latest indication that the coronavirus outbreak could provide a tailwind for biosimilars, as the firm gave an update on its biosimilars pipeline – including ranibizumab, ustekinumab, aflibercept and an undisclosed molecule, as well as other unrevealed projects – and how it has been affected by the pandemic.
With the formal, virtual kick-off meeting set for 23 July, US FDA and sponsors are looking at a transformed landscape as they discuss what the next five years of user fees will look like.
Keeping Track: Approvals For Phexxi, Kynombi; New Claims For Lynparza, Alunbrig, Tecentriq; Intercept May Miss NASH User Fee Date
The latest drug development news and highlights from the Pink Sheet US FDA Performance Tracker.